EMA Widens Stakeholder Access To EU Adverse Drug Reaction Reports
This article was originally published in SRA
Executive Summary
Drug manufacturers, regulators, the public, health professionals and academia are to have greater access to information on suspected drug adverse reactions (ADRs) after the European Medicines Agency revised its policy on access to the adverse reaction database, EudraVigilance, to take account of changes in the EU pharmacovigilance legislation and other developments1,2.
You may also be interested in...
New EudraVigilance System To Usher In Simplified Reporting of ADRs From Nov. 22
The European Medicines Agency is asking drug companies and EU national competent authorities to prepare for the late November launch of the new EU pharmacovigilance database, which will have enhanced functionalities for reporting and analysing suspected adverse reactions.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.